Diet drug prevents Diabetes in people at high risk

Diet drug prevents Diabetes in people at high risk

According to the analysis of a scientific study currently in phase III, a diet drug that contains a combination of Phentermine and Topiramate reduces the risk of developing Type 2 Diabetes by up to 78.7%, in overweight or obese and those with metabolic syndrome or Pre-Diabetes.

By Joe Cardozo

In this study, Dr. WT Garvey and colleagues from the Department of Nutritional Sciences and the Center for Diabetes Training and Research of the University of Alabama, Birmingham, demonstrated the cardiometabolic benefits of this drug called Qsymia, which not only helps significantly reduce body weight of overweight or obese people, but also reduces the risk of developing Type 2 Diabetes by more than 78% in people with high risk factors for developing it.

These findings were based on an analysis of 475 patients in the initial trial (CONQUER) and then recorded in the following trial (SEQUEL) of this study, which lasted 108 weeks.

How was this study done?

In this study, whose initial trial was called CONQUER, 866 patients were divided into 2 groups. The participants of the first group received a placebo treatment while the other group was administered one of two doses of the drug. Participants in both groups received counseling about lifestyle changes and healthy eating.

A total of 475 volunteers who participated in the initial clinical trial CONQUER, which lasted 56 weeks, were selected to continue in the SEQUEL trial, which lasted 52 weeks and was conducted in 36 health centers. All of these participants had a high risk of developing Type 2 Diabetes, from which 315 or 66.31% had prediabetes, 451 or 94.74% had metabolic syndrome and 292 or 61.47% had both.

What were this study’s results?

After the 2 clinical trials which lasted 108 weeks (27 months), Dr. Garvey and his team of researchers reported that there was an average body weight reduction of 12.1% in those receiving high doses of the drug (Qsymia), when compared with the 10.9% who received small doses of Qsymia and only 2.5%, weight loss among those who were treated with a placebo and nutritional counseling.

In relation to the percentage reduction in the annual incidence of Type 2 Diabetes, between both groups, the analysis showed that in those receiving high doses of Qsymia, there was a 78.7% prevention of Diabetes diagnoses and 70.5% among those who received low doses of the drug, when compared to those treated with placebo and nutritional counseling. These findings also significantly showed an improvement in cardiometabolic parameters among the participants.

The reduction magnitude for the annual incidence rate of Diabetes, however, was directly related to the percentage of the participants’ body weight loss, regardless of the group they belonged to or the treatment they received. Those patients who lost less than 5% of their body weight had a higher annual incidence of Diabetes (6.3%), while those who lost at least 15% of their weight, had an annual incidence of diagnosed Diabetes of only 0.9%.

This study showed the efficacy and safety of the longterm use of Phentermine and Topiramate in overweight or obese people with a preexisting cardiometabolic disease (Metabolic Syndrome and/or prediabetes). This drug which contains a combination of these (Qsymia) also proved to have been well tolerated, both in those who got a low and high dose of the drug over the more than two years that this study lasted, stated Dr. Garvey and his colleagues.


It is well known that diabetes, along with Excess weight and Obesity, have become the biggest epidemics in recent times. With more than 385 million people with Diabetes worldwide and one out of four people with metabolic syndrome, it’s clear that reducing the high incidence of Diabetes is vital.

It’s not a secret either that lifestyle changes, healthy eating habits and more physical activity offer great benefits to lose excess weight and thus greatly reduce the risk of developing Type 2 Diabetes, among other cardiometabolic diseases.

Diabetes Up to Date celebrates the fact that we have one more tool for Diabetes Prevention

At Diabetes Up to Date we joyfully celebrate the results of this study, where it was again demonstrated that the risk factors for developing Type 2 Diabetes are significantly and proportionally reduced by the excess weight we lose, whether or not we take this medicine, demonstrating that this drug, by helping us lose weight, also helps prevent a Type 2 Diabetes diagnosis, even if we’re already at pre-diagnostic stages, such as metabolic syndrome and prediabetes.

Copyright © 2000 -2016- Diabetes Up to Date – All Rights Reserved

Total or partial reproduction of this article is prohibited.